PA
APLT

Profund Advisors’s Applied Therapeutics APLT Stock Holding History

Profund Advisors’s Portfolio APLT Stock Details APLT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-32,138
Closed -$273K – 1106
2024
Q3 		$273K Buy
+32,138
New +$189K 0.01% 858

Other funds holding APLT

VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Profund Advisors's APLT Position: Q4 2024 in Review

Profund Advisors sold out of Applied Therapeutics (APLT) in Q4 2024, closing a stake of 32,138 shares — an estimated $273K sold.

Profund Advisors first reported a position in APLT in Q3 2024 and held it in 1 quarter. The position peaked at $273K in Q3 2024. 118 funds tracked by Wall St. Rank hold APLT as of Q4 2024.

  • Profund Advisors reported no remaining Applied Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Profund Advisors sold 32,138 Applied Therapeutics shares in Q4 2024, an estimated $273K.
  • Profund Advisors first reported a position in Applied Therapeutics in Q3 2024 and held it in 1 quarter.
  • Profund Advisors's Applied Therapeutics position peaked at $273K in Q3 2024.
  • 118 funds tracked by Wall St. Rank held Applied Therapeutics as of Q4 2024.

Based on Profund Advisors's 13F filing for Q4 2024, filed 14 Feb 2025.